Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L H Boyle

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Tissue Antigens|February 28, 2015
TAPBPR: a new player in the MHC class I presentation pathwayC Hermann, J Trowsdale, L H Boyle
Rheumatology (Oxford, England)|March 11, 2003
Breaking the rules: the unconventional recognition of HLA-B27 by CD4+ T lymphocytes as an insight into the pathogenesis of the spondyloarthropathiesL H Boyle, J S Hill Gaston
Journal of Immunology (Baltimore, Md. : 1950)|August 18, 2001
The recognition of HLA-B27 by human CD4(+) T lymphocytesL H Boyle, J C Goodall, S S Opat, et al.
Seminars in Oncology|September 29, 2018
Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumabR T Casey, O Giger, I Seetho, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Tissue Antigens|February 28, 2015
TAPBPR: a new player in the MHC class I presentation pathwayC Hermann, J Trowsdale, L H Boyle
Rheumatology (Oxford, England)|March 11, 2003
Breaking the rules: the unconventional recognition of HLA-B27 by CD4+ T lymphocytes as an insight into the pathogenesis of the spondyloarthropathiesL H Boyle, J S Hill Gaston
Journal of Immunology (Baltimore, Md. : 1950)|August 18, 2001
The recognition of HLA-B27 by human CD4(+) T lymphocytesL H Boyle, J C Goodall, S S Opat, et al.
Seminars in Oncology|September 29, 2018
Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumabR T Casey, O Giger, I Seetho, et al.
Pageof 1